Immune Cell Landscape in the NSCLC Tumour Microenvironment: Molecular Dysregulation, Crosstalk and Insights into the CEMIP-STAT3-Mediated Immunosuppressive Axis.
Immunotherapy using immune checkpoint inhibitors has yielded meaningful clinical benefits for patients diagnosed with non-small cell lung cancer (NSCLC). Many patients still develop primary or acquired treatment resistance, a problem strongly tied to immunosuppressive features of the tumour microenvironment (TME). Mult...